32 results on '"Huerta, M."'
Search Results
2. Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma
3. 64P Integrative immune transcriptomic classification could improve patient selection for precision immunotherapy in advanced gastroesophageal adenocarcinoma
4. 379P Whole exome sequencing of plasma circulating tumor DNA identifies dynamic mutational changes to guide targeted therapies in colon cancer patients
5. 340P Prediction of relapse in colon cancer patients by machine learning models combining radiomics and deep features extracted from baseline computed tomography
6. 360P Epigenetic engineering on CDX2 allows to determine the interplaying consequences with other genetic and transcriptomic events in colorectal cancer
7. 583P COMPReS study: Multiomic profiling reveals organ-specific differences in metastases and identifies novel predictive biomarkers in relapsed localized colon cancer
8. New guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing
9. 488P Patient-derived organoids as a tool for modelling localized colorectal cancer
10. 1565P Clinical outcome after perioperative treatment on locally advanced and borderline pancreatic cancer: Experience of a single academic center
11. 420P Minimal residual disease detection and tracking tumour evolution using ctDNA in stage I-III colorectal cancer patients
12. 490P Metastatic colorectal cancer derived organoids recapitulate genomic profile and treatment response of the original tumor
13. 1493P An integrated analysis of gene expression profile and chromosomal aberrations highlighted the oxidative stress role in anti-HER2 drug-resistant gastric cancer models
14. 406MO Sequencing paired tumor DNA and white blood cells (WBCs) increases sensitivity to track plasma circulating tumor DNA (ctDNA) for detecting minimal residual disease (MRD) in localized colon cancer (CC)
15. Trifluridine/tipiracil in earlier lines of chemotherapy for advanced colorectal cancer
16. 1480P M2 macrophages could promote an immunosuppressive phenotype in a prospective cohort of advanced gastric cancer patients
17. Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype
18. Development of a living organoid biobank derived from colorectal cancer patients: Towards personalized medicine
19. NRF2 activation via PI3K/AKT/mTOR/RPS6 causes resistance to anti-HER2 agents among HER2 amplified gastric cancer
20. A multi-omic analysis for prospective patient stratification in localised colorectal cancer (CRC)
21. RPS6 through the activation of NRF2 causes resistance to antiHER2 drugs in HER2 amplified gastric cancer (GC) models
22. Gene expression changes responsible for lapatinib acquired resistance in HER2 positive gastric cancer cell lines: a microarray analysis
23. 638P - Development of a living organoid biobank derived from colorectal cancer patients: Towards personalized medicine
24. 522O - Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype
25. Neutrophil to lymphocyte ratio is a predictor of outcome in metastatic pancreatic cancer patients (MPC) treated with nab-paclitaxel and gemcitabine
26. Inhibition of PI3K pathway improves anti HER2 treatment efficacy in a panel of HER2 positive gastric cancer cell lines
27. LBA24 - A multi-omic analysis for prospective patient stratification in localised colorectal cancer (CRC)
28. 665P - NRF2 activation via PI3K/AKT/mTOR/RPS6 causes resistance to anti-HER2 agents among HER2 amplified gastric cancer
29. 100P - RPS6 through the activation of NRF2 causes resistance to antiHER2 drugs in HER2 amplified gastric cancer (GC) models
30. 41 - Gene expression changes responsible for lapatinib acquired resistance in HER2 positive gastric cancer cell lines: a microarray analysis
31. 691P - Neutrophil to lymphocyte ratio is a predictor of outcome in metastatic pancreatic cancer patients (MPC) treated with nab-paclitaxel and gemcitabine
32. 28P CNAs concordance between CRC-PDOs and the original tissue reveals relevant oncogenic pathways alterations.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.